GSK Welcomes Canadian Court Decision to Dismiss Proposed Zantac Lawsuit
May 12 2023 - 03:24AM
Dow Jones News
By Joe Hoppe
GSK said Friday that a proposed class action lawsuit surrounding
a heartburn treatment that it had marketed has been dismissed by a
court in Canada.
The pharma major said it welcomed the decision by the Supreme
Court of British Columbia and that it will continue to vigorously
defend proposed class actions filed in Ontario and Quebec by users
of ranitidine, the active substance in heartburn medication
Zantac.
In December, a U.S. judge dismissed a series of lawsuits--which
were measured in the tens of thousands--that alleged Zantac could
cause cancer. The judge concluded on Dec. 6 that there was no
scientific evidence to support the claim that the drug's active
substance ranitidine was carcinogenic.
In late March, the company said it disagreed with a ruling in
the Goetz case by the California state to allow a plaintiff's
experts to testify, and that there was no consistent or reliable
evidence that ranitidine increased the risk of any cancer
GSK said Friday that since 2019, there have been 13
peer-reviewed studies conducted regarding the use of ranitidine. It
said the scientific consensus is there is no consistent or reliable
evidence the substance increases the risk for any type of
cancer.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
May 12, 2023 03:09 ET (07:09 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Nov 2023 to Dec 2023
GSK (NYSE:GSK)
Historical Stock Chart
From Dec 2022 to Dec 2023